DCx Biotherapeutics Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Employees
  • 26

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 4

DCx Biotherapeutics General Information

Description

Developer of precision oncology therapeutics intended to revolutionize patient outcomes against genetically defined cancers. The company's platform, named music, integrates high-throughput functional screening, deep bioinformatics, and machine learning to identify synergistic intracellular and cell-surface targets and is focused on developing multi-modal antibody drug conjugates (MM-ADCs), enabling the biotechnology sector to access a new class of multi-modal, synergistic-targeting treatments with improved efficacy and tolerability against a range of tumor types.

Contact Information

Website
www.dcxbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3500-1133 Street Melville
  • Vancouver, British Columbia V6E 4E5
  • Canada
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 3500-1133 Street Melville
  • Vancouver, British Columbia V6E 4E5
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DCx Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 01-Mar-2026 Completed Generating Revenue
2. Accelerator/Incubator 28-Feb-2025 Completed Startup
1. Early Stage VC 01-Jan-2025 Completed Startup
To view DCx Biotherapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

DCx Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DCx Biotherapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Novateur Ventures Venture Capital Minority
Life Sciences BC Accelerator/Incubator Minority
Amplitude Ventures Venture Capital Minority
Repare Therapeutics Corporation Minority
To view DCx Biotherapeutics’s complete investors history, request access »

DCx Biotherapeutics FAQs

  • When was DCx Biotherapeutics founded?

    DCx Biotherapeutics was founded in 2025.

  • Where is DCx Biotherapeutics headquartered?

    DCx Biotherapeutics is headquartered in Vancouver, Canada.

  • What is the size of DCx Biotherapeutics?

    DCx Biotherapeutics has 26 total employees.

  • What industry is DCx Biotherapeutics in?

    DCx Biotherapeutics’s primary industry is Biotechnology.

  • Is DCx Biotherapeutics a private or public company?

    DCx Biotherapeutics is a Private company.

  • What is DCx Biotherapeutics’s current revenue?

    The current revenue for DCx Biotherapeutics is .

  • Who are DCx Biotherapeutics’s investors?

    Novateur Ventures, Life Sciences BC, Amplitude Ventures, and Repare Therapeutics have invested in DCx Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process